Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC.

doi:10.1007/s11864-012-0204-6

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Back to search

Article

Strategies for overcoming EGFR resistance in the treatment of advanced-stage NSCLC.

Current treatment options in oncology - 1 Dec 2012

Lovly Christine M, Horn Leora

Abstract excerpt

OPINION STATEMENT: Patients whose tumors harbor somatic-activating mutations within the epidermal growth factor receptor (EGFR) gene define a clinically distinct molecular cohort of lung cancers with increased sensitivity to the EGFR tyrosine kinase inhibitors (TKIs), including the "first-generation" reversible inhibitors, erlotinib and gefitinib, and the "second-generation" irreversible inhibitors, afatinib and...

Topics

Antineoplastic Agents
Carcinoma, Non-Small-Cell Lung
Disease-Free Survival
Drug Resistance, Neoplasm
ErbB Receptors
Erlotinib Hydrochloride
Gefitinib
Humans
Lung Neoplasms
Mutation
Protein Kinase Inhibitors
Quinazolines
Treatment Outcome

Source

Open in PubMed

Identifiers

PMID: 22833206
DOI: 10.1007/s11864-012-0204-6

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 31 Aug 2026.

Community interpretation

Discuss the evidence

Ask a question, add context or challenge an interpretation. Community activity is separate from scientific evidence strength.

discussions

replies

Citations encouraged

Claims remain attributable.

No discussion yet

Be the first to add a careful, cited interpretation.

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics